🧾 What This Document Is

This is a proxy statement (DEF 14A) for Royalty Pharma's 2026 Annual General Meeting. Think of it as an information packet and voting guide for shareholders. It explains what will be voted on at the meeting, provides details about the company's leadership and pay, and asks shareholders to approve several key items. Its main purpose is to give shareholders the information they need to vote their shares, either in person or by proxy.

🏢 What The Company Does

👉 In simple terms, Royalty Pharma is a specialized investment firm that buys royalty streams from biopharmaceutical companies. Instead of developing drugs itself, it provides cash upfront to drug developers (like biotechs) in exchange for a percentage of future sales from successful medicines. Their portfolio includes royalties on many leading biotech drugs. They essentially act as a "banker" or "partner" for innovation in life sciences.

📅 The Big Meeting

The Annual General Meeting is set for Thursday, June 4, 2026, at 9:00 a.m. ET in New York. The record date to vote was April 6, 2026. Shareholders can vote online, by phone, or by mail. The key items on the agenda are:

Elect 9 directors to the board.
Hold a non-binding vote on executive compensation ("Say-on-Pay").
Ratify the appointment of Ernst & Young LLP as the auditor.
Receive and vote on various UK-specific statutory reports and auditor matters.
Approve share buyback terms and authorize the board to issue new shares.

👥 Who's Running the Show? (The Board)

Shareholders will vote on a slate of 9 director nominees. Here’s a quick snapshot of their skills and independence:

Pablo Legorreta (Chairman & CEO): The founder. Not independent.
Ted Love, M.D. (Lead Independent Director): Former biotech CEO, very experienced.
Bonnie Bassler, Ph.D.: Princeton professor, renowned scientist.
Vlad Coric, M.D.: Biohaven CEO, physician-scientist.
Catherine Engelbert: Former Deloitte CEO, WNBA Commissioner.
Carole Ho, M.D.: Lilly Neuroscience President, joined board in 2025.
David Hodgson: General Atlantic Vice Chairman, finance expert.
Gregory Norden: Former Wyeth CFO, audit chair.
Elizabeth Weatherman: Warburg Pincus partner, joined board in 2025.

👉 Why it matters: The board is a mix of biopharma experts, finance veterans, and corporate leaders. Eight of the nine are independent, which helps ensure unbiased oversight of management.

🏛️ How the Company is Governed

The document highlights Royalty Pharma's governance practices:

Separation of Powers: Pablo Legorreta is both Chairman and CEO. A strong Lead Independent Director (Ted Love) leads independent director sessions and acts as a liaison.
Committee Structure: Three key committees, all made up of independent directors:
- Audit Committee (Gregory Norden, Chair): Oversees financials, risk, and auditors.
- Compensation Committee (David Hodgson, Chair): Sets executive pay.
- Nominating/Governance Committee (Ted Love, Chair): Recommends directors, oversees governance and corporate responsibility.
Shareholder Engagement: They report over 350 meetings with investors in 2025, showing active dialogue.
Share Ownership Rules: Directors and executives are required to own significant company stock, aligning their interests with shareholders.

💰 Executive Pay Vote

Shareholders are asked to approve, on a non-binding basis, the compensation of the named executive officers. This is the "Say-on-Pay" vote.

The company's philosophy is "pay-for-performance," meaning a large portion of executive pay is "at-risk" and tied to hitting performance goals.
The main components are base salary, an annual bonus, and long-term "Equity Performance Awards."

👉 Why it matters: This vote is a chance for shareholders to voice their opinion on whether the top executives are being paid appropriately for the company's performance. While non-binding, a strong "against" vote would send a significant message to the board.

📜 Other Key Proposals

Auditor Ratification: Shareholders will vote to ratify Ernst & Young LLP as the independent accounting firm. This is a standard annual procedure.
UK Statutory Items: As a UK-incorporated company (NYSE-listed), it also seeks votes to receive its UK accounts and approve the UK auditor's remuneration.
Share Capital Authorizations:
- Proposal 8: Approves the terms for the company to buy back its own Class A shares (a way to return capital to shareholders).
- Proposals 9 & 10: Authorize the board to issue new shares, with Proposal 10 seeking a special resolution (75% majority needed) to issue shares without pre-emptive rights (i.e., without offering them first to existing shareholders).

📈 Company Performance Snapshot

The CEO's letter highlights a strong 2025:

Returned over $1.7 billion to shareholders, including $1.2 billion in share repurchases.
Deployed $2.6 billion on new royalty acquisitions, including innovative deals with Revolution Medicines and BeOne Medicine.
Internalized its management structure, making it a fully integrated public company.
The Board added two new directors with deep biopharma (Dr. Ho) and finance (Ms. Weatherman) expertise.

🧠 The Analogy

Royalty Pharma is like a specialized venture capital fund for drug royalties. This proxy statement is the annual "LP (Limited Partner) meeting" where the shareholders (the ultimate backers) get to review the fund's performance, vote on the key partners (the board), and approve the rules of the fund (auditors, share buybacks). The CEO is the fund manager reporting back on how he deployed their capital to buy future income streams from drug sales.

🧩 Final Takeaway

This proxy statement is fundamentally about shareholder oversight and governance. It provides the tools for investors to elect a qualified, independent-heavy board, give feedback on executive pay, and approve the financial stewards of the company. The strong performance highlights in the CEO's letter set the context for why management believes its strategy and leadership deserve continued support.

Royalty Pharma Sets June 4 Meeting to Vote on Directors and Pay